home / stock / glpgf / glpgf short
Short Information | Galapagos Genomics Ord (OTCMKTS:GLPGF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 6,567 |
Total Actual Volume | 312,570 |
Short Trends | |
---|---|
Cover Days | 6 |
Short Days | 12 |
No Change Days | 2 |
Averages | |
---|---|
Average Short Volume | 328 |
Average Short Percentage | 64.05% |
Is there a GLPGF Short Squeeze or Breakout about to happen?
See the GLPGF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-26-2023 | $41.7 | $41.75 | $41.75 | $41.7 | 150 | 150 | 100% |
06-20-2023 | $41.6 | $41.6 | $41.6 | $41.6 | 5,000 | 5,000 | 100% |
03-01-2023 | $37.97 | $37.97 | $37.97 | $37.97 | 125,032 | 32 | 0.03% |
10-05-2021 | $50.65 | $50.65 | $50.65 | $50.65 | 80,031 | 31 | 0.04% |
09-27-2021 | $55 | $55 | $55 | $55 | 5 | 5 | 100% |
09-21-2021 | $53.5 | $54.3 | $54.5 | $53.5 | 133 | 15 | 11.28% |
08-20-2021 | $54.25 | $55.85 | $55.85 | $54.25 | 187 | 45 | 24.06% |
07-23-2021 | $51 | $59.5 | $59.5 | $51 | 1,000 | 500 | 50% |
07-15-2021 | $57.475 | $57.5 | $57.5 | $57.475 | 100,100 | 100 | 0.1% |
06-24-2021 | $69.02 | $69.02 | $69.02 | $69.02 | 100 | 100 | 100% |
05-10-2021 | $70.99 | $71.5 | $71.5 | $70.99 | 160 | 150 | 93.75% |
04-29-2021 | $79 | $79 | $79 | $79 | 93 | 93 | 100% |
04-23-2021 | $81.2598 | $81 | $81.2598 | $81 | 42 | 20 | 47.62% |
04-22-2021 | $82.9 | $82 | $82.9 | $82 | 219 | 22 | 10.05% |
04-19-2021 | $79.5 | $79.5 | $79.5 | $79.5 | 12 | 12 | 100% |
04-12-2021 | $78 | $78 | $78 | $78 | 26 | 26 | 100% |
04-09-2021 | $77.7279 | $78.25 | $78.25 | $77.7279 | 25 | 11 | 44% |
02-23-2021 | $86.5 | $86.5 | $86.5 | $86.5 | 113 | 113 | 100% |
02-22-2021 | $86.5 | $86.5 | $86.5 | $86.5 | 113 | 113 | 100% |
02-12-2021 | $86.1 | $86.1 | $86.1 | $86.1 | 29 | 29 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Galapagos Genomics Ord Company Name:
GLPGF Stock Symbol:
OTCMKTS Market:
Galapagos Genomics Ord Website:
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual Euro...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown enc...
BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centers Collaboration enables rapid deployment of Galapagos' decentralized CAR-T platform across the U.S., improving patient access ...